# Anti–Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/anti-tumor-necrosis-factor-versus-tocilizumab-in-the-treatment-of-refractory/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Mathilde Leclercq,Anaïs Andrillon,Georgina Maalouf,P. Sève,P. Bielefeld,J. Gueudry,Thomas Sené,T. Moulinet,Bénédicte Rouvière,D. Sène,A.C. Desbois,F. Domont,Sara Touhami,Carolla El Chamieh,P. Cacoub,Bahram Bodaghi,Lucie Biard,David Saadoun |
| Citations | 78 |
| DOI | 10.1016/j.ophtha.2021.11.013 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.aaojournal.org/article/S0161642021009003/pdf |
| OpenAlex ID | https://openalex.org/W3214460730 |
| PMID | 34793830 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Sara Touhami](https://scholariq.org/researchers/sara-touhami/)

## Paper journal

- [Ophthalmology](https://scholariq.org/journals/ophthalmology/)

## Paper primary topic

- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)

## Paper topics

- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)
- [Sarcoidosis and Beryllium Toxicity Research](https://scholariq.org/topics/sarcoidosis-and-beryllium-toxicity-research/)
- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.